In this blog post, we will examine the ethical and scientific issues surrounding embryonic stem cell research and use, and consider whether they should be permitted.
Recently, research teams in South Korea and abroad have been actively conducting clinical trials targeting various intractable diseases using stem cell-based therapies, including embryonic stem cells, and meaningful treatment outcomes have been reported in some areas. As a result, embryonic stem cells have established themselves as a crucial subject of research in the fields of life sciences and medicine and are viewed as a new source of hope for those suffering from intractable and incurable diseases. In line with this societal trend, embryonic stem cell research is steadily progressing, and economic support and investment for research and development are also continuously expanding. In fact, many countries are promoting stem cell research as a strategic technology for the future at the national level and implementing various forms of support policies. Consequently, interest in and investment in embryonic stem cell research continue to grow not only in South Korea but also around the world.
Proponents of embryonic stem cell use emphasize that these cells can be used to treat intractable and incurable diseases. Embryonic stem cells are pluripotent stem cells derived from early-stage embryos and possess the ability to differentiate into cells of various tissues and organs. Therefore, supporters argue that using these cells can increase the likelihood of treating various intractable diseases, including Parkinson’s disease. Furthermore, they believe that if technologies for producing transplantable tissues or organs using embryonic stem cells advance, this could help alleviate the current shortage of organs. However, despite the immense potential of embryonic stem cell research, it is a field where it is difficult to reach a definitive conclusion, as it involves potential risks, ethical issues, and various social controversies.
The greatest weakness of embryonic stem cells lies in ethical concerns. Since the process of extracting stem cells from early-stage embryos is required, it gives rise to a fundamental ethical debate over where to draw the line regarding the beginning of life. Those who prioritize the dignity of life argue that, since an embryo is an entity with the potential to develop into a human being, using it for research purposes constitutes a violation of that dignity. From this perspective, the very act of using embryos is viewed as incompatible with bioethics. On the other hand, while there are those who emphasize the necessity of research, the controversy surrounding embryonic stem cells is likely to continue unless sufficient social consensus is reached on these ethical issues.
There are also concerns that if technologies utilizing embryonic stem cells are commercialized and widely adopted, they could give rise to other social problems. If many people come to prefer cells, tissues, or organs with superior genetic traits, a phenomenon of excessive concentration of specific genetic characteristics could occur. While it is uncertain to what extent this situation might actually arise, concerns regarding a reduction in genetic diversity and bioethical issues are consistently being raised. To take an extreme example, one could imagine a scenario where the number of people with identical or very similar genetic characteristics increases across society. Furthermore, some express concern that a decline in genetic diversity could lead to an increase in certain genetic diseases. Of course, it is more appropriate to view this as a subject of ethical and social debate rather than a fact that has been clearly proven to date. Therefore, as embryonic stem cell technology advances, we must consider not only technical achievements but also genetic diversity and social impacts.
Furthermore, embryonic stem cells still face challenges that need to be addressed in terms of safety. To date, research into treatments using embryonic stem cells has been steadily advancing, and clinical trials and limited treatment successes have been reported for some diseases. However, most treatments are still at a stage where their long-term safety and efficacy must be continuously verified. In particular, given that embryonic stem cells possess an exceptional ability to differentiate into various cell types, ongoing research is examining the potential for tumor formation or unexpected side effects should differentiation not proceed precisely as intended. Furthermore, the possibility of problems such as immune rejection when tissues or organs produced using stem cells are transplanted into patients has not yet been fully resolved. Therefore, a cautious approach is necessary until sufficient safety is ensured.
Of course, it is possible that future technological advancements will resolve these safety issues to a significant extent. However, it is difficult to argue that this possibility alone sufficiently establishes the necessity and legitimacy of embryonic stem cell research, because alternatives to embryonic stem cells do exist. A prime example is “induced pluripotent stem cells (iPS cells).” Induced pluripotent stem cells are cells created by introducing specific genetic factors into adult somatic cells—such as skin cells—to give them properties similar to those of stem cells, without using fertilized eggs or embryos. Like embryonic stem cells, these cells can differentiate into various cell types, and because they use the patient’s own cells, they are highly likely to reduce the risk of immune rejection. Above all, because they do not use embryos, they have the advantage of largely resolving the most significant ethical issues associated with embryonic stem cells. Given the existence of such an alternative, careful consideration is needed regarding whether embryonic stem cells—which are the subject of significant ethical controversy—must necessarily be prioritized.
Supporters of embryonic stem cells sometimes argue for their necessity by pointing out that, in the early stages, induced pluripotent stem cells (iPSCs) were associated with low differentiation efficiency and concerns regarding genetic stability. However, since then, research has been continuously conducted worldwide to verify the safety and feasibility of iPSCs, and technologies for genetic stability and quality control have steadily advanced. Numerous studies have reported that stable cell lines can be secured when the research environment and culture methods are properly managed. Of course, iPSCs still face unresolved challenges, but their potential to replace embryonic stem cells is growing, and their scope of application in regenerative medicine and disease research continues to expand.
Research on iPSCs is currently underway at a vigorous pace, and research findings targeting various diseases are being published on an ongoing basis. While there were initial concerns regarding differentiation efficiency and safety, research aimed at overcoming these limitations has continued steadily as cell production and culture technologies have advanced. Furthermore, technologies for producing personalized cells using a patient’s own somatic cells are rapidly advancing and are being utilized in various fields, including regenerative medicine, new drug development, and disease model research. As such, induced pluripotent stem cells are gradually expanding their scope of application as an alternative to embryonic stem cells, and they pose relatively fewer ethical concerns since they do not involve the use of embryos. Therefore, I believe that as we continue to support and advance stem cell research in the future, it is necessary to conduct research in a way that takes into account both ethical considerations and practical applications.
In addition, there is another issue regarding embryonic stem cells that warrants deeper consideration. If embryonic stem cell technology advances to the point where transplantable organs can be mass-produced, the question arises as to whether the benefits of such cutting-edge medical technology can truly be provided equitably to everyone. It is difficult to be optimistic about this issue as well. Since advanced stem cell therapy technologies entail very high research, development, and manufacturing costs, there is a high likelihood that treatment costs will remain substantial even after commercialization. Consequently, patients with sufficient financial means may be the first to benefit from these medical technologies, while patients facing economic hardship might not have adequate access to treatment—even if they suffer from the same disease.
Supporters of embryonic stem cell research argue that this science offers new hope to patients with intractable and rare diseases, saves lives, improves quality of life, and upholds human dignity. However, if cutting-edge medical technologies are made available only to certain segments of the population, this may not expand human dignity but could instead further widen the gap in access to healthcare. Ultimately, for stem cell technology to truly contribute to human life, not only technological advancement but also the public nature and equity of healthcare must be considered.
It is difficult to deny that embryonic stem cells hold tremendous potential for advancement. In fact, important research is continuously being conducted in the fields of regenerative medicine and the treatment of intractable diseases, and there is a high likelihood of new breakthroughs in the future. However, as discussed earlier, embryonic stem cells also raise ethical and safety concerns, as well as social issues related to access to healthcare and equal opportunity. If these issues are adequately resolved, there is certainly potential for embryonic stem cells to make a significant contribution to human progress. However, at this point in time, it is difficult to say that these issues have been completely resolved.
Furthermore, induced pluripotent stem cells (iPSCs)—an alternative to embryonic stem cells—are also undergoing continuous development. Of course, iPSCs also face challenges that need to be addressed, but through various recent studies, their applicability and safety are steadily improving, and they are establishing themselves as an important subject of research in regenerative medicine. Given the existence of such alternatives, careful societal discussion is needed regarding whether the use of embryonic stem cells should be actively expanded, even at the cost of enduring controversies surrounding the beginning of life and human dignity.
To uphold human dignity, we must consider not only the advancement of science and technology but also bioethics and social responsibility. Throughout history, humanity has strived tirelessly to strike a balance between scientific progress and ethical values. Stem cell research, too, must develop within this balance, and bioethics must not be neglected simply because of technical feasibility. Humanity currently stands at a critical crossroads in determining the direction of future medical technology. Therefore, stem cell research and application must be pursued cautiously, taking into comprehensive consideration not only scientific potential but also ethics, safety, and social equity.
